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The prognosis of patients with de novo myelodysplastic syndrome (MDS) who are red blood cell transfusion–
dependent (TD) and receive supportive care is inferior to that of patients who do not require transfusions.
Whether TD also affects outcome after allogeneic transplantation is unknown. Consequently, in 172 de novo
MDS patients (median age, 51 years), we analyzed the impact of TD on outcome after high-dose conditioning
and allogeneic peripheral blood stem cell transplantation (PBSCT). With a median follow-up of 37 months,
the probability of 3-year overall survival (OS) did not differ significantly between patients who were TD and
those who were not TD before PBSCT (P5 .1); however, transfusion burden, as reflected by ferritin levels,
was correlated with a greater probability of severe acute graft-versus-host disease (aGVHD; P 5 .03) and
a higher comorbidity index (P 5 .01), and OS was inferior in those patients with a ferritin level .1000 mg/
L before PBSCT (P5 .03). In multivariate analysis, only marrow myeloblast count (P5 .01) and comorbidity
index (P5.001) had a significant impact on OS. Our data do not identify TD as an independent negative prog-
nostic factor for outcome after allogeneic PBSCT’ however, iron overload (presumably transfusion-related)
may contribute to poor transplantation success by adding to the overall comorbidities. Whether clinical in-
tervention in the form of iron chelation can improve the outcome of allogeneic PBSCT in TD patients with
MDS remains to be determined.
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Several therapeutic modalities for patients with
myelodysplastic syndrome (MDS) have been devel-
oped over the past few years, some of which may
change the natural course of the disease [1]. With the
rare exception of patients who achieve long-lasting re-
mission with chemotherapy, allogeneic hematopoietic
stem cell transplantation (HSCT) is currently the only
modality with proved curative potential [2]. But given
the heterogeneity of MDS and the potential complica-
tions associated with HSCT, deciding when and in
whom to perform allogeneic HSCT often is difficult.
The decision model presented by Cutler et al. [3]
showed a survival advantage with early transplantation
in patients with MDS classified as intermediate-2 or
high risk based on International Prognostic Scoring
System (IPSS) criteria [4]; however, that analysis was
based largely on observations antedating the availabil-
ity of new drugs and did not incorporate more recent1217
1218 Biol Blood Marrow Transplant 14:1217-1225, 2008U. Platzbecker et al.information on factors that might affect the disease
course, such as comorbidity, transfusion dependence
(TD), or iron overload. The identification of additional
clinical markers that might help in selecting patients
likely to benefit from allogeneic HSCT and in deter-
mining the optimum time point for HSCT is desirable.
The need for red blood cell transfusion support re-
gardless of IPSS score has been shown to have a nega-
tive impact on overall survival (OS) in patients who did
not undergo transplantation [5]. The reason for this is
not entirely clear. Patients who become TD may have
amore aggressive disease biology. They alsomay expe-
rience adverse effects related to transfusion-induced
allosensitization or may suffer toxic organ effects re-
lated to iron overload. The finding of a negative impact
of TD on prognosis has led to the development of
a new proposed scoring system for patients with de
novo MDS: the World Health Organization Interna-
tional Prognostic Scoring System (WPSS), which
merges the parameters of theWorld Health Organiza-
tion’s (WHO) classification of MDS with the IPSS,
essentially by having TD replace the ‘‘cytopenia’’ cat-
egory of the IPSS [6].
Whether TD also is an independent risk factor in
patients undergoing allogeneic HSCT remains un-
known. A potential negative effect of TD on transplan-
tation outcome has been derived indirectly from
a study by Armand et al. [7] in 103 patients with
MDS (including therapy-related MDS, for which the
scoring systems have not been validated) that sug-
gested a possible link between pretransplantation ferri-
tin level and outcome after allogeneic HSCT using
conventional conditioning regimens. In that study,
the negative impact of iron overload appeared to be in-
dependent of the effects of graft-versus-host disease
(GVHD). Other possibilities are that transfusion
needs and ferritin levels were related to disease stage
or disease duration and, associated with this, a long
history of transfusion support.
We performed a retrospective study involving 6
transplantation centers in Germany, Austria, and the
United States to analyze results in 172 patients with
de novo MDS undergoing allogeneic HSCT using
granulocyte colony-stimulating factor (G-CSF)–
mobilized peripheral blood stem cells (PBSCs) after
high-intensity conditioning.
MATERIALS AND METHODS
Patient and disease characteristics
The study cohort comprised 172 patients with de
novo MDS (Table 1). The patients were classified ac-
cording to French-American-British (FAB), WHO,
IPSS, and WPSS criteria at the time of transplanta-
tion. According to Malcovati et al. [6], TD was
defined as having received at least one unit of redblood cells within the 8-week period before PBSCT.
The precise number of units of red blood cells trans-
fused was not consistently available. Only 4 patients
underwent transplantation within 2 months of diag-
nosis. The most recent ferritin level, obtained not
more than 6 weeks before PBSCT, was considered
for analysis. Pretransplantation comorbidities were
assessed using the hematopoietic cell transplantation
comorbidity index (HCT-CI) [8]. Comorbidity scores
could be assigned to 164 patients; the breakdown by
score was as follows: 0, 74 patients; 1, 31 patients; 2,
19 patients; 3, 20 patients; 4, 13 patients; and $ 5, 7
patients.
DNA-based HLA-typing of donor and recipient
was performed for HLA-A, -B, -DRB1, and -DQB1
and by intermediate resolution for HLA-C. Ten pa-
tients received single-locus allele HLA-mismatched
transplants. Thirty-seven patients had received induc-
tion chemotherapy before PBSCT, 17 of whom
achieved complete remission (CR).
Transplantation regimens
Conditioning regimens were busulfan (Bu)-based
(total Bu dose, 16 mg/kg over 4 days orally or i.v.).
In all patients, Bu was combined with cyclophospha-
mide (Cy; total dose, 120 mg/kg over 2 days; n 5
142), Cy 1 etoposide (total dose of etoposide 30 mg/
kg; n 5 9), or fludarabine (Flu; 120-150 mg/m2 over
5 days; n5 20). Sixteen patients received rabbit antith-
ymocyte globulin (ATG; thymoglobulin) as part of
the conditioning regimen, as described previously
[9]. PBSCs were infused on day 0 with no further
manipulation.
GVHD prophylaxis
GVHD prophylaxis included a calcineurin in-
hibitor (cyclosporine [CsA; n 5 159] or tacrolimus
[n 5 13]), combined with methotrexate (MTX; n 5
152), everolimus (n 5 12), or mycophenolate mofetil
(MMF; n 5 8).
Regimen-related toxicity
Regimen-related toxicity was scored using the Na-
tional Cancer Institute’s Common Toxicity Criteria
(CTC), version 3.0 (http://ctep.cancer.gov/report-
ing/ctc.html). Acute and chronic GVHD (aGVHD,
cGVHD)were diagnosed and graded using established
criteria [10,11]. Death after relapse was defined as
a death due to relapse regardless of the proximate
cause. Death without relapse was classified as a nonre-
lapse death. Infection was listed as the cause of death
when a bacterial, viral, or fungal infection was the
proximate cause of death in patients who had not expe-
rienced relapse. GVHD was considered a contributor
to death if active GVHD was present at the time of
death from any cause in the absence of relapse.
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All Patients (n 5 172), n Non-TD (n 5 41), n (%) TD (n 5 131), n (%) P
FAB classification NS
RA/RARS 85 18 (44) 67 (51)
RAEB 52 18 (44) 34 (26)
RAEB-t 16 2 (5) 14 (11)
MDS/AML 19 3 (7) 16 (12)
WHO classification .004
5q syndrome 5 0 (0) 5 (4)
RA/RARS 14 0 (0) 14 (11)
RCMD/RCMD-RS 64 19 (46) 45 (34)
RAEB-1 24 7 (17) 17 (13)
RAEB-2 27 10 (24) 17 (13)
AML 35 5 (12) 30 (23)
MDS-U 3 0 (0) 3 (2)
IPSS classification .01
LOW 9 2 (5) 7 (6)
INT-1 77 18 (47) 58 (53)
INT-2 42 16 (43) 26 (24)
HIGH 21 2 (5) 19 (17)
WPSS classification NS
Very low 0 0 (0) 0 (0)
Low 21 8 (22) 13 (12)
Intermediate 38 10 (27) 27 (25)
High 66 17 (47) 48 (45)
Very high 10 1 (4) 9 (8)
Median age at treatment, years (range) 51 (10-68) 53 (21-64) 50 (10-68) NS
Median time from diagnosis to treatment,
months (range)
8.5 (0.1-243) 8.7 (0.4-35) 8.5 (0.1-243) NS
Related/unrelated donor, n 90/82 18/23 72/59 NS
HLA mismatch, n 10 1 (2) 9 (7) NS
Median CD34 cells/kg (range) 6.76 (1.3-32.2) 7.49 (2.07-18.7) 6.67 (1.3-32.2) NS
CMV seropositivity, n 54 15 39 NS
Median follow-up, months (range) 37 (0.5-135) 49.1 (0.5-97) 37.1 (0.8-135) NS
CMV indicates cytomegalovirus.
Note. The patients were grouped according to red blood cell transfusion dependence and the current classification and scoring systems used in MDS,
including FAB, WHO, IPSS, and WPSS.Statistical analysis
All patients provided written informed consent and
were treated according to institutional review board–
approved protocols at the respective institutions.
This retrospective study was performed within the
German-Austrian MDS Study Group together with
the Fred Hutchinson Cancer Research Center in Seat-
tle, in compliance with the Declaration of Helsinki.
Estimates of survival and disease-free survival were ob-
tained by the Kaplan-Meyer method; patients were
censored at last follow-up if still alive [12]. The cumu-
lative incidences of relapse (CI-R) and nonrelapse
mortality (CI-NRM) were calculated using cumulative
incidence estimates [13]; the log-rank test was used to
compare variables in different groups of patients. Mul-
tivariate Cox regression analyses were carried out to
determine the effects of various variables on survival.
Data were analyzed as of December 1, 2007.
RESULTS
Patient outcome by FAB, WHO, and IPSS
classifications
With a median follow-up of 37 months, the esti-
mated 3-year OS was 52%, with an apparent plateaufor surviving patients (Figure 1A). When patients
were grouped by FAB category, outcome was, as ex-
pected, most favorable in refractory anemia (RA)/re-
fractory anemia with ringed sideroblasts (RARS)
patients (3-year OS, 60%); OS was lower in patients
with more advanced disease, including refractory ane-
mia with excess blasts (RAEB) (44%; P 5 .04) and
RAEB in transformation (RAEBt) (30%; P 5 .007),
and for patients whose MDS had evolved to acute
myelogenous leukemia (AML) (53%; P 5 not sig-
nificant [NS]). The outcome in the latter was presum-
ably related to the fact that most of these patients
received induction chemotherapy before undergoing
transplantation.
Grouping by WHO categories allowed for a
further separation of subgroups with different out-
comes compared with FAB categories (Table 1); how-
ever, some groups contained only small numbers of
patients and thus are not included in Figure 1B. For
patients with del(5q) with RA/RARS and the few pa-
tients with MDS unclassified (MDS-U), the 3-year
OS was 60%, 57%, and 67%, respectively. The 3-year
OS was 59% for patients with refractory cytopenia
with multilineage dysplasia (RCMD)/RCMD with
ringed sideroblasts (RCMD-RS), 52% for those with
RAEB-1, 36% for those with RAEB-2, and 43% for
1220 Biol Blood Marrow Transplant 14:1217-1225, 2008U. Platzbecker et al.months
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Figure 1. Outcome after allogeneic PBSCT. A, All patients (n 5 172), B, Patients grouped according to the WHO classification. Patients with del(5q)
and MDS-U are not shown because of small numbers, The differences between patients with RCMD/RS and RAEB-2 (P 5 .01) or MDS/AML (P 5 .04)
were statistically significant.those with MDS/AML. The differences between
patients with RCMD/RS and RAEB-2 (P 5 .01) or
MDS/AML (P 5 .04) were statistically significant.
In agreement with earlier observations, which
showed that the IPSS risk predicted posttransplanta-
tion outcome in patients with MDS [14], there was
a significant difference between patients in risk cate-
gory INT-1 (3-year OS, 53%) and INT-2 (59%) ver-
sus those in risk category HIGH (37%) (P 5 .05 and
P 5 .02, respectively).
The impact of TD on survival after
transplantation
As shown in Table 1, 131 of the 172 patients were
TD before PBSCT. Although the groups were compa-
rable by FAB categories, they did differ byWHO clas-
sification (P5 .004). This difference was related to the
fact that the TD group contained patients who, based
on other criteria, had a very good prognosis, such as
patients with del(5q) or RA/RARS, who presumably
would not have undergone transplantation if they
were not TD. In addition, there were significantly
more INT-2 patients (P 5 .01) in the cohort that
was not TD. Patient and transplantation characteris-
tics, including HCT-CI [8] (data not shown), were
comparable in both groups (Table 1).
A total of 167 and 148 patients were evaluable for
aGVHD and cGVHD, respectively. Of the entire pa-
tient cohort, 62% developed aGVHD grade II-IV;
there was no difference between the groups (P 5 .24,
data not shown). The same was true for cGVHD(P 5 .22, data not shown), which occurred in 68% of
all patients.
The TD group contained significantly more pa-
tients with low risk features (byWHO and IPSS crite-
ria) and tended to have lower OS compared with the
non-TD group. In fact, as shown in Figure 2A, the es-
timated 3-year OS was 60% in the non-TD group,
compared with 49% in the TD group (P 5 .1). There
were no significant differences between CI-R and CI-
NRM (data not shown; P5 .27 and 0.37, respectively).
There was a trend for better survival in favor of non-
TD patients in the RAEB group (3-year OS, 36% vs
56%; P 5 .1)
We next incorporated TD into the classification
and grouped patients according to the recently devel-
oped WPSS categories. There were no patients in
WPSS risk group ‘‘very low,’’ reflecting the selection
of patients for allogeneic HSCT in clinical practice.
As shown in Figure 2B, the 3-year OS was 60% for
low- and intermediate-risk patients, 48% for high-
risk patients, and 50% for very-high-risk patients by
WPSS criteria (P 5 NS). Because TD is an integral
component of the WPSS score, the impact of TD
was not analyzed separately.
The3-yearOS for IPSS INT-1, INT-2, andHIGH
patients whowereTDor non-TDwas 50%versus 62%
(P 5 .38), 59% versus 61% (P 5 .48), and 36% versus
50% (P5 .6), respectively. The LOW risk group con-
tained too few patients to allow a valid analysis. Analysis
of cytogenetic risk categories (by IPSS criteria) in terms
of TD status revealed no significant differences (Fig-
ure 3), although a trend was seen in the intermediate
Biol Blood Marrow Transplant 14:1217-1225, 2008 1221Transfusion-Dependence and Allogeneic PBSCT in MDSmonths
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Figure 2. OS of all patients according to transfusion dependence. A, No TD (n 5 41) versus TD (n 5 131) (P 5 .1). B, By WPSS score.risk group in favor of non-TD patients (73%; n 5 12)
compared with TD patients (43%; n5 28) (P5 .1).
Ferritin level and transplantation outcome
Because pretransplantation ferritin levels recently
have been shown to be associatedwith a significantly in-
ferior OS (due to excessive NRM) [7], we evaluated
whether ferritin, as a surrogate marker of TD, was cor-
relatedwithoutcome in thesemostly nonchelatedMDS
patients. (Only 8 patients had received chelating ther-
apy before PBSCT.) The median pretransplantation
ferritin value for all patients was 924 mg/L (range, 27
to 6500 mg/L). As expected, there was a statistically sig-
nificant difference in ferritin levels between TD and
non-TD patients (median ferritin levels 1281 vs 150
mg/L; P\ .001). In clinical practice, 1000 mg/L often
serves as a trigger to initiate chelation therapy. There-
fore, patients were first grouped by ferritin levels below
or above 1000 mg/L. Patients with a ferritin above 1000
mg/L (n5 57) had a significantly lower 3-year OS than
patients with lower levels (38% vs 55%, P 5 .03). Al-
though there was a higher incidence of NRM (47% vs
30%) and relapse (20% vs 10%) in the group with ferri-
tin. 1000mg/L, the differences did not reach statistical
significance (P5 .3). The analysis was then extended to
patients with ferritin . 2500 mg/L [7]. As shown in
Figure 4A, 3-year survival was significantly inferior
among patients with ferritin levels above this threshold
(28% vs 50%; P5 .03). The relapse incidence was sim-
ilar for the 2 groups (data not shown), providing a cir-
cumstantial argument against a link between higher
ferritin levels and advanced/high-risk disease, which
was further supported by the absence of a correlation
of disease stage with ferritin levels (data not shown).In fact,NRMtended tobe higher in patientswith exces-
sive ferritin (P 5 .09) (Figure 4B). We then compared
the prevalence of grade II-IV aGVHD in patients
with respect to ferritin levels. The prevalence of grade
III-IV aGVHD in patients with ferritin values . 2500
mg/L (but not .1000 mg/L; P 5 .5) was significantly
higher than in patients with lower ferritin levels (46 %
vs 18 %; P5 .031); no differences were seen in the pa-
tients with cGVHD (data not shown).
Excessive iron overload can lead to chronic dam-
age in multiple organs. Sorror et al. [8] have shown
that pretransplantation comorbidities, including dys-
function of various organs (as categorized by the
HCT-CI), have a profound impact on transplantation
outcome. Consequently, we analyzed whether ferritin
levels were correlated with the HCT-CI. Results,
given in Figure 5, show that iron overload was signifi-
cantly associated with a higher HCT-CI (P 5 .01).
Multivariate analyses
As shown in Table 2, only the HCT-CI (P 5 .001)
and theFAB classification (P5 .01) remained significant
for posttransplantationoutcome inmultivariate analysis.
Patient age (./\50 years), IPSS category, cytogenetics,
number of CD341 cells transplanted, TD, ferritin level
(./\1000 mg/L), CMV serostatus, HLA mismatch, or
donor type had no statistically significant impact.
DISCUSSION
The main objective of this retrospective analysis
was to determinewhetherTD, recognized as a negative
prognostic factor in patients with de novo MDS man-
aged with supportive care, also affects prognosis in
1222 Biol Blood Marrow Transplant 14:1217-1225, 2008U. Platzbecker et al.months
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Figure 3. OS by cytogenetic risk (IPSS criteria) and TD. A, Good risk (P 5 .4); B, intermediate risk (P 5 .1); C, poor risk (P 5 .8).patients who have undergone allogeneic PBSCT. The
data demonstrate no significant overall disadvantage
for TD patients. Within the limits of a retrospective
analysis, the data suggest that the negative prognostic
impact of TD in patients who did not undergo trans-
plantation can be overcome by PBSCT. It should be
emphasized, however, that in the report on TD by
Malcovati et al. [5], the median patient age was 66
years, compared with 51 years in the present study.
Older patients are more likely to have preexisting or-
gan dysfunction (comorbidities), and may be moreprone to organ dysfunction and death related to the ad-
ditional iron loading as a consequence of transfusions.
Furthermore, the biology of LOW/INT-1 MDS may
be less aggressive in younger patients than in those
over age 50 years [15].
Our TD cohort included significantly more pa-
tients with less-advanced MDS as determined by con-
ventional criteria. In contrast, the proportion of TD
patients was lower in the cohort with more advanced
MDS, possibly because in those patients disease pro-
gression was more rapid, and parameters other than
Biol Blood Marrow Transplant 14:1217-1225, 2008 1223Transfusion-Dependence and Allogeneic PBSCT in MDSmonths months
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Figure 4. OS (A) and cumulative incidence of NRM (B) were dependent on pretransplantation ferritin level (A, P 5 .03; B, P 5 .09).TD determined the timing of HSCT. This scenario is
further supported by the impact of cytogenetic risk
groups on PBSCT outcome. In patients with the
high-risk karyotype, TD did not affect survival; the
negative impact of the karyotype appeared to be
the overriding factor, in agreement with several recent
reports [16,17]. The data suggest that among patients
with a low- or intermediate-risk karyotype, those not
requiring transfusions fared better. This was parti-
cularly true for the intermediate-risk group. That
category comprises a broad spectrum of karyotypic
abnormalities that may have very different prognostic
significance [16], and thus TD may come into play as
an additional factor.
In an attempt to connect TD with iron overload,
we analyzed the present data also dependent on ferritinlevels. In agreement with the findings of Armand et al.
[7] and others [18], the current data suggested that ex-
cessively elevated ferritin levels had a negative impact
on posttransplantation outcome, related to higher
rates of NRM and possibly more severe aGVHD.
Our results imply that the negative effect of iron, as re-
flected by elevated ferritin levels, was present already at
ferritin levels of 1000 mg/L. This is noteworthy be-
cause in general, chelation is not initiated until levels
of 1000 or higher are reached [19]. Because the present
study determinedTD status as well as ferritin level, the
data suggest that TD can be a negative risk factor, al-
though the retrospective analysis did not show a direct
significant correlation.
Preliminary data in patients managed with non-
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Figure 5. Pretransplantation ferritin level and transplant comorbidity index (HCT-CI) (P5.01). A statistically significant (P5.01) association was found
between pretransplantation ferritin level and the HCT-CI.
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No analogous data are available for patients undergo-
ing transplantation, although several autopsy studies
have shown an association between iron overload and
an increased likelihood of NRM [18,21], in particular,
invasive mold infections [22]. If TD were a risk factor
for transplantation outcome, then it might be consid-
ered a ‘‘comorbid condition,’’ and its impact could be
analyzed in the context of the recently established
HCT-CI [8]. Given our observation of a correlation
of iron overload with the HCT-CI, it may be specu-
lated that iron chelation can result in improvement of
comorbidities, whichmay affect patient outcome, espe-
cially after intensive treatment, such as PBSCT.
Because the intensity of transplantation conditioning
affectsNRM, it would be of interest to extend the pres-
ent analysis to patients undergoing allogeneic HSCT
after reduced-intensity conditioning (RIC) [23-31].
In summary, this retrospective study suggests some
relevant associations among pretransplantation trans-
fusion, iron overload, and transplantation outcome.
TD was not shown to be an independent risk factor,
however. Definitively addressing this question requires
controlled prospective trials. Nevertheless, continuous
transfusions will lead to iron accumulation, which
tends to result in inflammatory changes (and possibly
also to up-regulation of ferritin) and, directly or indi-
rectly, higher NRM. Iron overload/ferritin levels pos-
sibly should be incorporated into the currently used
HCT-CI. Patients who are considered candidates for
PBSCT may benefit from iron chelation aimed at pre-
venting excessive iron overload. Conceivably, alloge-
neic PBSCT should be considered earlier in the
disease course in patients with MDS who are TD.
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Table 2. Multivariate Analysis of Factors Affecting OS
Variable
Odds
Ratio
95% Confidence
Interval P
Age < 50 or > 50 years 0.86 0.44-1.65 .6
FAB 2.54 1.22-5.30 .01
IPSS 0.87 0.44-1.71 .7
Cytogenetics 1.25 0.82-1.90 .3
Graft CD34+ cells/kg 0.97 0.90-1.04 .4
CMV status 1.24 0.64-2.39 .5
HLA mismatch 0.46 0.13-1.57 .2
Donor type (related/unrelated) 0.77 0.40-1.46 .4
TD 1.68 0.76-3.70 .2
Ferritin >/< 1000 mg/L 0.67 0.33-1.35 .3
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